ScinoPharm Taiwan announced its consolidated revenue for the first half of 2024, totaling NT$1.646 billion, with a net profit of NT$215 million, marking a 117% increase compared to the same period last year. The company’s strategic investments in plant upgrades and production line optimizations have paid off, with increased capacity utilization driving strong operational performance and nearly double-digit growth in U.S. dollar-denominated revenue in the first half of 2024.
During the first half of the year, ScinoPharm Taiwan continued to meet customer demands, delivering products and services on schedule. The company saw significant growth in its contract development and manufacturing organization (CDMO) business, particularly from the sales of epilepsy and oncology drugs, with several products expected to maintain strong shipment momentum in the second half of the year. The performance of its formulation business also remained robust, with stable supply following the successful mass production and market launch of injectable products for U.S. customers last year.
Notably, in March, ScinoPharm’s injectable plant in Taiwan and its active pharmaceutical ingredient (API) plant in Changshu, China (SciAnda), both passed U.S. FDA inspections with zero Form 483 observations. This achievement marks the eighth consecutive time since 2015 that ScinoPharm’s facilities in Taiwan and China have passed FDA inspections with zero deficiencies, underscoring the company’s consistent commitment to high standards in production and quality management, reaffirming its world-class manufacturing capabilities.
Looking ahead, ScinoPharm is optimistic about a new CDMO project for an Alzheimer's treatment drug, where the client recently obtained FDA approval, with plans to launch the product in the U.S. market in 2025. As the client prepares for market entry, ScinoPharm expects to leverage this momentum for future shipments. Other CDMO clients are also aligning their New Drug Application (NDA) submissions based on clinical trial results, with potential market approvals in the next two years. Should these approvals be granted, ScinoPharm is poised to support customer timelines and increase revenue growth.
In the injectables sector, ScinoPharm continues to ramp up production and delivery of injectable drugs according to customer demand, while also expanding its offerings to include new contract manufacturing items and services. Additionally, in response to evolving regulatory trends, ScinoPharm has proactively expanded its pharmaceutical testing services over the past two years, further enhancing its analytical capabilities.
Regarding its subsidiary, SciAnda (Changshu) Pharmaceuticals, the first half of 2024 saw significant growth in both API and CDMO services, driven by the transition of several CDMO projects into commercial-scale production and the approval of customer products for market launch. The recent FDA inspection success with zero deficiencies is expected to bolster SciAnda’s business prospects with international pharmaceutical companies and clients in both the U.S. and China, contributing to ongoing growth momentum.
ScinoPharm Taiwan remains committed to its core strengths in API manufacturing while aggressively developing and promoting new products. The company’s strategic focus is on integrating its proprietary APIs, injectable products, and CDMO services to offer a comprehensive, end-to-end solution that enhances overall profitability.
Resource (mandarin): 台灣神隆H1表現優 加大布局針劑及CDMO業務
